Recursion Pharmaceuticals
RXRX
2.45
-0.27
-9.93%
Recursion Pharmaceuticals
US · RXRX
#2649 by market cap
Listed 2021
2.45
-0.27
-9.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Quant vs Street three independent views, side by side
StockVane factor grade
D
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 4 analysts
Buy
Avg price target 6.63 +170.6%
Price target rangecurrent 2.45
Low5.90
Avg6.63
High8.00
Buy 50%
Hold 50%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-04 | BofA Securities | -- | Hold | 6.00 |
| 2026-10-19 | Needham | -- | Buy | 8.00 |
| 2026-10-16 | BofA Securities | -- | Hold | 6.00 |
| 2026-10-16 | Morgan Stanley | -- | Hold | 5.90 |
| 2026-09-21 | BofA Securities | -- | Hold | -- |
| 2026-09-15 | J.P. Morgan | -- | Buy | -- |
| 2026-08-17 | Morgan Stanley | -- | Hold | 5.30 |
| 2026-08-12 | BofA Securities | -- | Hold | 6.00 |
| 2026-08-07 | BofA Securities | -- | Hold | 6.00 |
| 2026-08-05 | TD Cowen | -- | Hold | -- |
| 2026-08-05 | Needham | -- | Buy | 8.00 |
| 2026-05-14 | Morgan Stanley | -- | Hold | 5.50 |
| 2026-05-13 | BofA Securities | -- | Hold | 6.00 |
| 2026-05-07 | BofA Securities | -- | Hold | 6.00 |
| 2026-05-07 | Needham | -- | Buy | 8.00 |
| 2026-05-06 | TD Cowen | -- | Hold | -- |
| 2026-04-30 | J.P. Morgan | -- | Buy | 10.00 |
| 2026-04-14 | Needham | -- | Buy | 8.00 |
| 2026-02-25 | TD Cowen | -- | Hold | -- |
| 2026-02-25 | BofA Securities | -- | Hold | 6.00 |
| 2026-02-25 | Needham | -- | Buy | 8.00 |
| 2026-01-14 | BofA Securities | -- | Hold | 7.00 |
| 2026-01-12 | BofA Securities | -- | Hold | 7.00 |
| 2026-01-06 | BofA Securities | -- | Hold | 7.00 |
| 2025-12-17 | J.P. Morgan | -- | Buy | 11.00 |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | After close | ±10.93% | -3.92% (in line) |
| 2026/Q2 | 2026-08-05 | -- | ±8.09% | -4.23% (in line) |
| 2026/Q1 | 2026-05-06 | -- | ±8.09% | +1.78% (in line) |
| 2025/Q4 | 2026-02-25 | -- | ±7.60% | +6.80% (in line) |
| 2025/Q3 | 2025-11-05 | -- | ±10.60% | -0.80% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±13.93% | -4.66% (in line) |
| 2025/Q1 | 2025-05-05 | -- | ±16.77% | -16.58% (in line) |
| 2024/Q4 | 2025-02-28 | -- | ±15.97% | -2.09% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±14.48% | -0.57% (in line) |
| 2024/Q2 | 2024-08-08 | -- | ±22.81% | +4.24% (in line) |
| 2024/Q1 | 2024-05-09 | After close | ±13.75% | -0.46% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±26.20% | -16.62% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.
Recursion Pharmaceuticals discussion 0 comments